Teachers Advisors LLC Raises Holdings in Acorda Therapeutics (ACOR)

Teachers Advisors LLC raised its stake in shares of Acorda Therapeutics (NASDAQ:ACOR) by 12.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 88,694 shares of the biopharmaceutical company’s stock after buying an additional 10,106 shares during the period. Teachers Advisors LLC owned about 0.19% of Acorda Therapeutics worth $1,902,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ACOR. Nationwide Fund Advisors raised its stake in shares of Acorda Therapeutics by 25.7% during the 3rd quarter. Nationwide Fund Advisors now owns 146,207 shares of the biopharmaceutical company’s stock valued at $3,458,000 after buying an additional 29,891 shares during the last quarter. American International Group Inc. raised its stake in shares of Acorda Therapeutics by 5.6% during the 3rd quarter. American International Group Inc. now owns 34,712 shares of the biopharmaceutical company’s stock valued at $821,000 after buying an additional 1,839 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Acorda Therapeutics by 11.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,655,959 shares of the biopharmaceutical company’s stock valued at $62,813,000 after buying an additional 283,091 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Acorda Therapeutics during the 3rd quarter valued at about $541,000. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Acorda Therapeutics by 7.1% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 302,836 shares of the biopharmaceutical company’s stock valued at $6,496,000 after buying an additional 20,148 shares during the last quarter.

How to Become a New Pot Stock Millionaire

Shares of Acorda Therapeutics stock opened at $23.35 on Tuesday. The company has a current ratio of 3.07, a quick ratio of 2.81 and a debt-to-equity ratio of 0.64. Acorda Therapeutics has a twelve month low of $13.60 and a twelve month high of $29.60.

Acorda Therapeutics (NASDAQ:ACOR) last announced its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.88 by ($0.27). Acorda Therapeutics had a negative net margin of 37.97% and a negative return on equity of 4.88%. The business had revenue of $188.40 million during the quarter, compared to analysts’ expectations of $171.70 million. During the same quarter in the prior year, the firm earned $0.05 EPS. Acorda Therapeutics’s revenue for the quarter was up 34.0% on a year-over-year basis. research analysts predict that Acorda Therapeutics will post -0.94 EPS for the current year.

In related news, insider David Lawrence sold 31,000 shares of Acorda Therapeutics stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $27.58, for a total value of $854,980.00. Following the completion of the transaction, the insider now owns 5,275 shares in the company, valued at approximately $145,484.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 7.90% of the stock is owned by insiders.

ACOR has been the subject of a number of recent research reports. JPMorgan Chase reiterated a “hold” rating on shares of Acorda Therapeutics in a research note on Tuesday, January 9th. Zacks Investment Research lowered Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. HC Wainwright reiterated a “buy” rating and set a $31.00 price objective (down previously from $34.00) on shares of Acorda Therapeutics in a research note on Wednesday, January 17th. Oppenheimer lifted their price objective on Acorda Therapeutics from $18.00 to $21.00 and gave the company a “market perform” rating in a research note on Wednesday, January 31st. Finally, Goldman Sachs upgraded Acorda Therapeutics from a “sell” rating to a “neutral” rating in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company. Acorda Therapeutics has a consensus rating of “Hold” and an average price target of $21.83.

ILLEGAL ACTIVITY NOTICE: “Teachers Advisors LLC Raises Holdings in Acorda Therapeutics (ACOR)” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2018/04/17/teachers-advisors-llc-raises-holdings-in-acorda-therapeutics-acor.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Want to see what other hedge funds are holding ACOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acorda Therapeutics (NASDAQ:ACOR).

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply